SCHEMBL3307362

SCHEMBL3307362

CC(C)(NC(=O)[C@H]1CC[C@H](c2ccc(NC(=O)COc3cccc(Cl)c3)cc2)CC1)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.48
MAPT P10636 1/20 0.48
ALDH1A1 P00352 1/20 0.48
NOTUM Q6P988 2/20 0.46
TP53 P04637 1/20 0.46
GAA P10253 1/20 0.46
ALOX12 P18054 1/20 0.46
CETP P11597 2/20 0.43
HTT P42858 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
MAOB P27338 1/20 0.41
POLB P06746 1/20 0.41
IDO1 P14902 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3307357 1.00 LMNA (0.48) LMNAMAPTALDH1A1NOTUMTP53
SCHEMBL14113407 1.00 LMNA (0.48) LMNAMAPTALDH1A1NOTUMTP53
SCHEMBL3301439 0.90 NPC1 (0.48) LMNAMAPTALDH1A1GAANPC1
SCHEMBL14113481 0.90 NPC1 (0.48) LMNAMAPTALDH1A1GAANPC1
SCHEMBL3301443 0.90 NPC1 (0.48) LMNAMAPTALDH1A1GAANPC1
SCHEMBL3296853 0.89 ALDH1A1 (0.52) LMNAMAPTALDH1A1GAAMEN1
SCHEMBL14113694 0.89 ALDH1A1 (0.52) LMNAMAPTALDH1A1GAAMEN1
SCHEMBL3296857 0.89 ALDH1A1 (0.52) LMNAMAPTALDH1A1GAAMEN1
SCHEMBL3299613 0.79 NAMPT (0.49) MAPTALDH1A1GAANPC1RAB9A
SCHEMBL3299610 0.79 NAMPT (0.49) MAPTALDH1A1GAANPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES PROSIDION LIMITED (GB) 2010-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093733-A1 AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES CPS1, GOT2, GPR119 LMNA 3562/4885MAPT 1308/4885ALDH1A1 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.